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TransthyretinTransthyretin (TTR) is a plasma and cerebrospinal ﬂuid (CSF)-circulating homotetrameric protein. More than
100 point mutations have been identiﬁed in the TTR gene and several are related with amyloid diseases. Here
we focused our attention in the TTR L12P variant associated with severe peripheral neuropathy and
leptomeningeal amyloidosis. By using different cell lines derived from tissues specialized on TTR synthesis,
such as the hepatocyte and the choroid plexus expressing WT, V30M, or L12P TTR variants we analyzed se-
cretion, intracellular aggregation and degradation patterns. Also, we used liver-speciﬁc AAV gene transfer
to assess expression of the L12P variant in vivo. We found the following: (i) decreased secretion with intra-
cellular aggregation of TTR L12P in hepatoma cells relative toWT and V30M variant; this differential property
of TTR L12P variant was also observed in mice injected with L12P AAV vector; (ii) differential N-glycosylation
pattern of L12P variant in hepatoma cell lysates, conditioned media and mouse sera, which might represent
an escape mechanism from ERAD degradation; (iii) intracellular L12P TTR aggregates mainly localized to ly-
sosomes in cultured cells and liver; and (iv) none of the above ﬁndings were present in choroid plexus de-
rived cells, suggesting particular secretion/quality control mechanisms that might contribute to
leptomeningeal amyloidosis associated with the L12P variant. These observations open new avenues for
the treatment of TTR associated leptomeningeal amyloidosis.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Amyloidoses are a large group of diseases caused mainly by protein
misfolding, aggregation and deposition. Transthyretin (TTR) is one of
these amyloidogenic proteins involved mainly in peripheral nerve am-
yloidosis, as it is the case of familial amyloidotic polyneuropathy (FAP)
[1]. TTR is a 127 amino acid soluble and typical non-glycosylated protein
mainly synthesized and secreted by hepatocytes in the liver, the choroid
plexus epithelium in the brain and retinal epithelium in the eye. It is re-
sponsible for the transport of thyroxine (T4) in plasma and cerebrospi-
nal ﬂuid (CSF). To date more than 100 point mutations have been
described in the TTR gene at 50 different codons, but not all are associ-
ated with disease (http://amyloidosismutations.com/mut-attr.php).
The most common TTRmutation responsible for FAP is the substitution
of valine bymethionine at position 30 of the polypeptide chain (V30M).
In FAP, extracellularmutant TTR deposits extracellularly systemically in
the form of non-ﬁbrillar and amyloid ﬁbrils in most organs and tissues,lar Neurobiology, IBMC, Rua do
351 226074900; fax: +351
rights reserved.except for liver parenchyma and the central nervous system. There are
exceptional cases where mutated TTR leads to cerebral compromise, as
a result of TTR amyloid deposits in the leptomeninges and subarachnoid
blood vessels but almost no deposition in visceral organs [2–4]. The rea-
son for these differences in organ targeting are still unknown, but some
TTR variants appear to have more tendency to have CNS involvement
than others, e.g. L12P, D18G or A25T [4,5]. These leptomeningeal amy-
loidoses are uncommon but fatal and treatments are yet to be found,
since the available therapies for TTR amyloidosis, such as liver trans-
plantation or pharmacological approaches do not seem to affect the
protein in the CSF [6]. However, in L12P-TTR amyloidosis, severe sys-
temic amyloidosis and intracellular deposits in the liver were reported
[3].
TTR is produced as a monomer, assembles as a tetramer in the ER,
can undergo post-translational modiﬁcations and then is secreted.
TTR amyloidogenesis occurs by a rate-limiting tetramer dissociation,
followed by partial monomer unfolding, leading to aggregate forma-
tion and eventually amyloid ﬁbril assembly [7]. The presence of mu-
tations in the monomeric chain may lead to decreased tetrameric
folding efﬁciency within the ER and reduced export, as well as to
reduced thermodynamic stability [8]. The protein thermodynamic
and kinetic stabilities have a potential effect on secretion efﬁciency.
Most TTR variants associated with CNS pathology have low scores of
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ERAD degradation and low secretion, as shown in BHK cells [8].
Transfection experiments in rat choroid plexus cells showed that
TTR variant A25T was secreted as efﬁciently as WT but not D18G
(both variants are associated with CNS pathology and low plasma
levels). This suggests that choroidal cells have higher secretion apti-
tude than other cell types [8].
The main objectives of the present work were to compare the secre-
tion efﬁciency ofWT, L12P, V30M, andD18GTTRmutants in hepatocytes
and choroid plexus cells. Additionally, we used intravenous delivery of
AAV vectors to achieve liver-speciﬁc expression of L12P TTR variant
and the WT protein in adult mice. These somatic transgenic mouse
models were developed and characterized to investigate the different
modes of secretion/intracellular degradation by liver to understand
ethiopathogenesis and future treatments for TTR related leptomeningeal
amyloidosis, including, among others the L12P variant.2. Materials and methods
2.1. TTR-TC plasmids
Brieﬂy, for the construction of the TC-FlAsH tag we used the follow-
ing aminoacid sequence: Gly-Ala-Gly-Gly-Cys-Cys-Pro-Gly-Cys-Cys-
Gly-Gly-Gly. This sequence was fused to the N-terminal of human TTR
cDNA, which was then cloned into NheI and XhoI sites of the
CSCW2-IRES-mCherry lentiviral vector [9]. Expression of the vector is
driven by the CMV promoter. V30M, L12P and D18G TTR variants
were generated with the QuickChange site-directed mutagenesis kit
(Agilent) according to the manufacturer's instructions and using the
wild type TTR vector as a template.2.2. Lentiviral production
Lentiviral vector stocks were produced as previously described [9].
Titers were determined on human 293T cells as transducing units
(tu) using serial dilutions of vector stocks and infection in the
presence of 8 μg/mL polybrene (Millipore).2.3. Cell culture
HEK293 cell line (human embryonic kidney, European Collection of
Cell Cultures) was cultured in EMEM (Eagle's minimum essential
media, Lonza), supplemented with 10% (w/v) FBS, 2 mM L-glutamine,
100 U/mL penicillin/streptomycin (all from Gibco) and 1% (w/v)
non-essential amino acids (Sigma-Aldrich). SaHep cell line (human
hepatoma without TTR expression, kindly provided by Dr. João
Monjardino, Imperial College, London, UK) was cultured in DMEM
(Dulbecco's modiﬁed Eagle's medium, Lonza), supplemented with 10%
(w/v) FBS, 2 mM L-glutamine and 100 U/mL penicillin/streptomycin
(all from Gibco). TR-CSFB cell line (rat immortalized epithelial choroid
plexus cells, kindly gifted by Dr. Terasaki, Tohoku University, Japan) was
cultured in DMEM with 4.5 g/L glucose (Gibco), supplemented with
10% (w/v) FBS, 2 mM L-glutamine, 100 U/mL penicillin/streptomycin
and 1% (w/v) sodium pyruvate (all from Gibco). All cell lines were
routinely propagated in T-25 ﬂasks in monolayer (SaHep were grown
on ﬂasks coated with collagen I) at 37 °C (HEK293 and SaHep) or 33 °C
(TR-CSFB), in 5% CO2 humidiﬁed atmospheres.
Cells were plated in 24 well plates and 24 h later were infected
with the lentivirus vectors at a multiplicity of infection (M.O.I.) =
100 tu/cell in the presence of 8 μg/mL polybrene. Forty-eight hours
after infection, cells were assayed for expression of the transgenes
by measurement of mCherry expression, yielding on average 90% of
infected cells with no apparent toxicity. Cells were then propagated.2.4. Protein expression assessment
Cells were plated in multi-well plates of 6 wells. Twenty-four hours
later, medium was changed to serum-free DMEM without phenol red
supplemented with 2 mM L-Glutamine. After 24 h, conditioned media
were collected and cells were washed with ice-cold PBS and lysed in
RIPA buffer (50 mM Tris–HCl, 150 mM NaCl, 1 mg/mL sodium
deoxycholate, 1% NP-40) containing 1× protease inhibitors mixture
(GE Healthcare Bioscience). Total protein in cell lysates was determined
by the Bio-Rad assay kit (Bio-Rad) using serial dilutions of bovine serum
albumin as protein standard; 40 μg of total protein was separated in a
15% polyacrylamide SDS-PAGE gel and then transferred onto a 0.2 μm
pore nitrocellulosemembrane (Whatman) using awet system. Primary
antibodies were rabbit polyclonal anti-hTTR (Dako, 1:1000) andmouse
monoclonal anti-α-tubulin (Sigma-Aldrich, 1:10,000) for normaliza-
tion. The enhanced chemiluminescense method (ECL, GE Healthcare
Bioscience) was used to develop the blots. Quantitative analysis of
western blot images was performed using the ImageJ software (NIH).
As for the media, samples were centrifuged at low speed to remove
cell debris, subsequently dialyzed against water buffered to pH 7 and
then freeze-dried. Samples were resuspended in 200 μL of distilled
water and TTR concentration measured by ELISA, as previously de-
scribed [10].
2.5. N-glycosylation assays
N-glycosylation was assessed with a glycoprotein deglycosylation
kit (Calbiochem) according to the manufacturer's instructions. Brieﬂy,
20 μL of media or 100 ug of total protein was incubated with or with-
out (for control) N-glycosidase F for 3 h at 37 °C. Samples were then
loaded in a 15% polyacrylamide SDS-PAGE gel and then blotted as
above described.
In tunicamycin assays, the different cell lines were plated on 6-well
multiplates. Twenty-four hours after plating, culture media were re-
placed with serum-free DMEM without phenol red supplemented
with 2 mM L-glutamine in the presence of 1 ug/mL tunicamycin
(Sigma-Aldrich). After 24 h conditioned media and cell lysates were
collected and processed as above described. In parallel control experi-
ments, 6-well multiplates were incubated with vehicle alone (DMSO).
2.6. Fluorescence microscopy
For live cell imaging by ﬂuorescence analysis, cells were plated on
μ-Slide 8 well (Ibidi) and 24 h after plating subjected to FlAsH stain-
ing, nucleus staining and incubation with 75 nM LysoTracker Red
DND-99 (Molecular Probes, Invitrogen) for 2 h for tracking of lyso-
somes, according to the manufacturer's instructions. After labeling,
cells were maintained in complete medium phenol red free and
live-imaged under a Laser Scanning Confocal Microscope Leica SP2
AOBS SE, with controlled temperature and using laser lines of
405 nm, 514 nm and 561 nm.
For ﬂuorescent and immunoﬂuorescence analyses in ﬁxed cells, cells
were grown on glass coverslips coated with either poly-D-lysine
(HEK293 and TR-CSFB) or collagen I (SaHep). Twenty-four hours after
plating, FlAsH staining was performed as described [11]. Brieﬂy,
cells were incubated for 30 min at 37 °C with 5 mM sodium
2-mercaptoethane sulfonate and 0.5 mM Tris(2-carboxyethyl) phos-
phine hydrochloride solution (both from Sigma-Aldrich) in OptiMEM
(Gibco). Cells were then washed and incubated with 1 μM FlAsH-EDT
solution (Molecular Probes, Invitrogen) in HBSS for 1 h at 37 °C,
followed by washes with 250 μM 1,2-ethanedithiol (EDT, Sigma-
Aldrich) in HBSS. After staining, cells were washed 3 times with HBSS
and incubated with 1 μM Hoechst 3342 (Molecular Probes, Invitrogen)
for nucleus stain and ﬁxed with ice-cold acetone for indirect immuno-
ﬂuorescence. Fixed cells were blocked with 1% BSA/PBS/0.25% Triton
X-100 for 1 h at room temperature and incubated overnight at 4 °C
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calize the ER or rabbit polyclonal antibody against LC3A/B (1:100, Cell
Signaling) to localize autophagosomes. For detection of primary anti-
bodies, AlexaFluor-647 anti-rabbit IgG (Molecular Probes, Invitrogen)
was used (1:1000, 30 min RT). Coverslips were mounted in Vectashield
(Vector Labs) and visualized under a Laser Scanning Confocal Micro-
scope Leica SP2 AOBS SE using laser lines 405 nm, 514 nm and 633 nm.
2.7. Lysosomal inhibition and autophagy enhancing treatments
The different cell lines were plated on 6-well multiplates. Twenty-
four hours later, culture media were replaced with serum-free DMEM
without phenol red supplemented with 2 mM L-glutamine in the pres-
ence of either 20 mM ammonium chloride (Sigma-Aldrich) or 5 mM
rapamycin (Calbiochem). After 24 h, conditionedmedia and cell lysates
were collected and processed as above described. Six-well multiplates
were incubated in parallel as control experiments with respective
vehicle —water (NH4Cl) or DMSO (rapamycin).
2.8. Animal procedures
Mice were handled according to European Union and National
rules. TTR KO mice [12] in the 129/Sv background, were maintained
at 24 ± 1 °C under a 12 h light/dark cycle and fed regular chow and
tap water ad libitum. Three months old animals were injected in
the tail vein with 3 × 1011 genome copies of scAAV2/8-AHA-TTR
L12P-W. Three months after injections the animals were euthanized
after anesthesia with a mixture of ketamine/medetomidine and
blood was collected, as well as liver that was ﬁxed in 4% neutral buff-
ered formalin and embedded for parafﬁn processing.
2.9. AAV vector design and preparation
The AAV vector used in this study was modiﬁed from pAAV-
CBA-mBgal-W [13] by removing the mBgal cDNA and replacing the
CBA promoter with a liver speciﬁc enhancer–promoter combination
composed of the human apolipoprotein hepatic control region
(HCR) and human alpha-1-antitrypsin gene promoter followed by
the hAAT 5′ untranslated region and a modiﬁed SV40 intron as previ-
ously described [14]. This enhancer-promoter was synthesized by
PCR ampliﬁcation and matches the sequence published by Nathwani
and colleagues [14]. The vector was further modiﬁed into a
self-complementary design by deletion of the terminal resolution
site (as described in [15]) in the AAV2 inverted terminal repeat
(ITR) near the AHA promoter to generate the plasmid scAAV-
AHA-W. WT or variant TTR cDNAs were cloned into this plasmid by
PCR ampliﬁcation followed by sequencing. Vector stocks made with
AAVrh8 capsid were produced by transient transfection of 293T
cells and puriﬁcation by iodixanol gradient centrifugation followed
by anion-exchange chromatography using HiTrapQ columns (GE
Healthcare), as described [16]. Titers of vector stocks were deter-
mined by real-time quantitative PCR using primers and probe speciﬁc
for the bovine growth hormone polyadenylation signal present in
these vectors, and represented as genome copies/mL.
2.10. Serum TTR levels and mass spectrometry
Serum TTR was quantiﬁed by ELISA [10], as above described for
conditioned media. For western blot analysis of sera, 5 μL of sera
was then loaded in a 15% polyacrylamide SDS-PAGE gel and then
blotted as above described.
MALDI mass spectroscopic analysis of TTR was performed after
immunoprecipitation with anti-TTR antibody (Dako) and band exci-
sion from a silver stained gel and digestion with trypsin followed
by identiﬁcation of the originated peptides from the SWISSPROT
database.2.11. Liver ﬂuorescence microscopy
Three-μm-thick sections were depparaﬁnated in Histoclear (National
Diagnostics) and hydrated in a descendent alcohol series. Tissues were
permeabilized with 0.25% Triton X-100 in PBS for 10 min at room tem-
perature and then incubated with blocking buffer containing 1% BSA/
PBS/0.25% Triton X-100 for 1 h at room temperature and incubated
overnight at 4 °C with sheep polyclonal antibody against human TTR
(1:50, The Binding Site) and rabbit antibody against Lamp-2 (1:50,
Sigma) to localize lysosomes. For the detection of primary antibodies,
AlexaFluor-488 anti-sheep IgG and AlexaFluor-647 anti-rabbit IgG
(both Molecular Probes, Invitrogen) were used (1:1000, 30 min RT).
Slidesweremounted in Vectashieldwith 4′,6-diamidino-2-phenylindole
(DAPI, Vector Labs) and visualized under a Laser Scanning Confocal
Microscope Leica SP2 AOBS SE using laser lines 405 nm, 488 nm and
633 nm.
2.12. Image analyses
All confocal images were processed using Fiji software [17] and
plug-in ROI Proﬁler was used in co-localization analysis.
2.13. Statistical analysis
Experimental results shown are the average of at least three inde-
pendent experiments and are presented as mean ± SEM. Statistical
signiﬁcance was evaluated by one-way ANOVA with Bonferroni post
test. Differences were considered signiﬁcant for p b 0.05 or as desig-
nated. Statistical analysis was performed by GraphPad Prism 5.0 for
Mac OsX.
3. Results
3.1. Establishment of stable hepatocyte and choroid plexus cell lines for
the study of human TTR secretion after lentiviral tetracystein TTR fusion
infection.
Several studies have been performed to study the secretion pat-
tern of different TTR variants [5,8,18] mostly in cell lines that natural-
ly do not express the protein and thus partially mimic the expression
pattern of TTR in vivo, such as HeLa [18] or BHK cells [8]. In the present
work we used cell lines derived from liver and choroid plexus, main
sites of TTR synthesis and secretion [19]; the studies described below
were carried out in SaHep (human hepatocytes derived cells) and
TR-CSFB cell lines (rat choroid plexus epithelial cells immortalized)
[20]. Endogenous TTR expression was not detected in either cell line.
A third cell line, HEK293 (human embryonic kidney), was used as a con-
trol cell line for protein expression, since it is widely recognized as an
easy to transfect/infect cell line and a goodmodel for protein expression
studies [21].
Chimeric TTR variants (WT, V30M, L12P and D18G) carrying a
C-terminus six amino acids tetracystein (TC) tag (Fig. 1A) [22] were
used to study intracellular protein trafﬁcking after reaction with the
membrane-permeable biarsenical dye FlAsH-EDT2 (ﬂuorescein arsen-
ical helix binder, bis-EDT adduct) [22,23]. Lentivirus vectors encoding
each variant (Fig. 1A) were used to stably transduce SaHep, TR-CSFB,
and human HEK293 cell lines (Fig. 1B). Intracellular TTR protein
levels were comparable for all TTR variants in HEK293 and SaHep
cell lines; in contrast, in TR-CSFB cells the intracellular levels of TTR
variants V30M, L12P and D18G were approximately 40% lower than
in cells expressing WT TTR (Fig. 2A). TTR mRNA levels were compara-
ble for all TTR variants in each cell line (Supplemental data, Fig. S1).
This suggests that TTR variant turnover rate in TR-CSFB cells is altered
compared to wild type TTR.
Analysis of TTR secretion into the growthmedium by ELISA revealed
considerable differences across cell types and variants (Fig. 2B). Both in
Fig. 1. Expression of human TTR variants in different cell lines. A. Schematic representation of the lentiviral vector used to transduce the different cell lines (HEK293, SaHep and
TR-CSFB). This vector leads to expression of different human TTR variants (TTR-X, where X codes for WT, V30M, L12P or D18G) fused to a tetracysteine tag (TC). B. Direct ﬂuores-
cence analysis of L12P expressing cells. Scale bar, 5 μm.
Fig. 2. Levels of human TTR variants in the different cell lines. A. hTTR levels in cell lysates. Plots represent quantiﬁcation of hTTR relative to α-tubulin. The bottom panels depict
representative western blots. Besides TTR monomer, a band of higher molecular weight (approximately 19 kDa) is observed in HEK293, and SaHep cells and it is indicated by an
arrow. *p b 0.05; **p b 0.01; ***p b 0.001. B. hTTR levels measured in cell conditioned media by ELISA. In all plots error bars represent SEM from 3 individual experiments, each one
with duplicates. *p b 0.05; **p b 0.01; ***p b 0.001. C. Secretion of N-glycosylated L12P TTR. Western blot analysis of conditioned media from cells treated in vitro either with
N-glycosidase F or tunicamycin (D); HEK293 and SaHep secrete N-glycosylated L12P TTR, not observed in TR-CSFB cells; tunicamycin inhibits N-glycosylation. Arrows indicate
the N-glycosylated band (a) and TTR monomer (b).
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ELISA (it was detected at very low levels by immunoblotting —
unpublished data) consistent with previous ﬁndings in other cell
types [18,24]. Relative to theWT protein, the V30Mvariant level in con-
ditioned medium was comparable in HEK293 cells but lower in SaHep
reﬂecting differences in secretion pattern among the 2 cell types. As
for the L12P protein, lower levels were found in both SaHep and
HEK293 cell lines relative toWT and V30M proteins. In contrast, secret-
ed levels of V30M or L12P TTR were comparable to WT TTR levels in
TR-CSFB cells. Contrarily to the ﬁndings in HEK293 and SaHep cells,
D18G TTRwas secreted from TR-CSFB cells. Based on the differential se-
cretion of TTR L12P variant in hepatocytes and choroid plexus and the
association of this variant with CNS amyloidosis [3] we decided to
focus our attention on this variant, to support a model where TTR pro-
tein variants are processed differentially by cell types of different tissue
origins.
Recent work has shown that TTR might undergo N-glycosylation
[25], especially in the case of misfolded and destabilized variants, such
as the D18G variant. We then evaluated whether L12P was susceptible
to N-glycosylation. A higher molecular weight band (~2 kDa) was
detected in cell lysates and conditioned media from HEK293 and
SaHep cells expressing TTR L12P or D18G (Fig. 2C)with a concentration
of approximately 2.3% relative to the monomer. No clear higher molec-
ular weight form was detectable in cell extracts or conditioned media
from cells expressing TTR WT or V30M variant, most likely because
they did not expose the putative Asn98 for glycosylation and thus are
not glycosylated. Treatment of cell extracts or supernatant from TTR
L12P expressingHEK293 and SaHep cellswithN-glycosidase F eliminat-
ed the higher molecular weight band (Fig. 2C). This shows that this
form is due to N-glycosylation of TTR L12P in those cells. In addition
we treated TTR L12P expressing SaHep cells with tunicamycin, an
N-glycosylation inhibitor, and observed that L12P secretion decreased
considerably while intracellular level increased (Fig. 2D). However,
when the experiments were performed in TR-CSFB cells, no evidence
for L12P N-glycosylation was observed, in accordance with the notion
that glycosylation is cell-type speciﬁc [26,27], and can lead to different
glycosylated patterns for the same protein in different organs.
3.2. Comparative L12P intracellular localization in hepatocyte and
choroid plexus cell lines
To characterize L12P protein intracellular localization throughout
the regular secretory pathway we assessed by confocal microscopy
with appropriate markers, L12P distribution in the ER, Golgi appara-
tus, endosomes and lysosomes by either direct ﬂuorescence in live
cells or indirect immunoﬂuorescence in ﬁxed material. The behavior
of WT and V30M, L12P and D18G TTR variants in the three different
cell types used in the secretion studies was also compared.
First, none of the cell lines expressingWT-TTR revealed punctate-like
material suggestive of the existence of intracellular aggregates, which
were very evident in all D18G expressing cells (Fig. 3A); in V30M ex-
pressing cells very few aggregates were present, whereas in L12P ex-
pressing SaHep and HEK293 cells clear evidence of aggregates was
found. By contrast, there were no aggregates in TR-CSFB cells expressing
L12P. This observation is in agreement with the secretion data in
TR-CSFB cells (Fig. 2B). The data again support the notion that epithelial
cells of choroid plexusmay possess distinct protein secretion and quality
control machineries.
Next we assessed the sub-cellular localization of TTR protein and
aggregates in all cell types (Fig. 3). All TTR proteins show widespread
co-localization with calnexin, an ER resident chaperone, since they
are produced in the ER (Fig. 3A). However TTR aggregates did not ex-
hibit clear co-localization with calnexin (arrowheads in Fig. 3A),
suggesting that they were not degraded in the ER.
We investigated whether intracellular accumulation of aggregates
was caused by disruption of the normal secretory pathway. Cells werestained for the Golgi apparatus, but no abnormalities in Golgi vesicles
and TTR-TC aggregates were noticed, excluding retention of the
accumulated TTR variants in this compartment (Supplemental data,
Fig. S2).
3.3. TTR intracellular aggregates are targeted for degradation in
lysosomes
The ubiquitin–proteasome system (UPS) is one of the major sites
for degradation of abnormal proteins in cells [28]. We investigated
whether this system may be involved in removing the intracellular
TTR aggregates in HEK293 and SaHep cells. We found no evidence
of increased TTR ubiquitination in cells expressing any of the variants
compared to WT TTR (unpublished results); thus, the UPS does not
appear to play a major role in the clearance of intracellular TTR aggre-
gates in these systems.
Next we investigated the possible presence of TTR in lysosomes,
which are vesicles more often associated with degradation, but that
can also function as secretory vesicles [29,30]. Moreover we wanted
to assess the possibility of lysosomal-mediated degradation of TTR ag-
gregates. For this purpose, we used LysoTracker, a ﬂuorescent probe
highly selective for acidic cellular organelles in live cells. When we
overlapped the images of TTR-TC with LysoTracker Red (Fig. 3B) the
great majority of TTR protein aggregates were inside lysosomes in
HEK293 and SaHep cell lines, especially prominent for the D18G var-
iant in HEK293 cells. In TR-CSFB cells we found no overlap between
TTR-TC and LysoTracker ﬂuorescence, as we also did not detect intra-
cellular protein aggregates in this cell line.
Next we investigated the contribution of lysosomes to TTR aggre-
gate degradation by biochemical means, in particular for the L12P
variant. We made use of the lysosomal inhibitor ammonium chloride,
which is a weak base that increases cellular pH and inhibits lysosomal
proteolysis and phagosome–lysosome fusion [31]. Incubation of
L12P-TTR HEK293 cells with 20 mM ammonium chloride for 24 h
led to signiﬁcantly increased intracellular TTR levels (Fig. 4A) and
concomitant decrease in TTR concentration in condition media
(Fig. 4B); surprisingly in parallel experiments in SaHep cells, lyso-
some inhibition by ammonium chloride had opposite effects, i.e.,
lead to decreased L12P intracellular accumulation and increased
L12P secretion levels (approximately 40% change). We interpret
these results as an additional effect of ammonium chloride in the
folding of the variants, acting as a chemical chaperone in hepatocyte
derived cells. The same trend in the pattern of intracellular accumula-
tion versus secretion in HEK293 and SaHep cells also occurred for the
V30M variant although to a lesser extent. Lysosome inhibition had no
effect on D18G variant or WT TTR accumulation/secretion or in WT in
HEK293 or SaHep cells, or on any of the TTR proteins in TR-CSFB cells.
In summary, in choroid plexus derived cells TTR aggregates are not
generated and therefore, the lysosome does not play a role in L12P
disposal as it does in hepatocyte derived cells.
3.4. Other degradation pathways for intracellular degradation of TTR
aggregates: autophagy
Autophagy is a way for cells to dispose of aberrant cytosolic pro-
teins that accumulate in the ER, working in parallel with the UPR
and the UPS [32,33]. The involvement of autophagy in the degrada-
tion of intracellular generated TTR aggregates was investigated
by immunostaining of ﬁxed cells with an LC3-speciﬁc antibody.
Co-localization of TTR-TC and LC3 (a marker for autophagy) was not
particularly evident in HEK293 and TR-CSFB cells, but apparent for
some TTR variants in SaHep cells (Fig. 5A). To further assess the po-
tential role of autophagy, we treated all three TTR-expressing cell
lines with rapamycin, but found no signiﬁcant changes in TTR levels
in cell lysates (Fig. 5B) or conditioned media (Fig. 5C) compared
to vehicle (DMSO) treated cells. Altogether this data suggest that
Fig. 3. Intracellular distribution of hTTR variants in different cells — distinct distribution in TR-CSFB as compared with HEK293 and SaHep cell lines. A. TTR-TC (green) co-localizes
with calnexin (red). TTR aggregates (white arrow heads) appear as punctated stain in variants V30M (scarce distribution), L12P and D18G inside HEK293 and SaHep cells but not in
TR-CSFB cells, indicating their retention inside the cell. Nuclei are stained with Hoechst 33342 (blue). TR-CSFB cells present some speckles in nuclei, result of non-speciﬁc staining.
Scale bars, 5 μm. B. TTR-TC (green) is co-localized with lysosomes (red) in live cells. Protein aggregates inside the lysosomes (in yellow, pointed by white arrow heads), mostly in
the cases of L12P and D18G in HEK293 and to a lesser extent in SaHep and absent in TR-CSFB cells. TR-CSFB cells present some speckles in nuclei, result of non-speciﬁc staining. Scale
bars, 5 μm.
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Fig. 4. Effect of ammonium chloride in TTR secretion. Plots represent hTTR levels in cell lysates with and without ammonium chloride treatment (A) measured by Western blot
relative to α-tubulin and in conditioned media (B) measured by ELISA. Error bars represent SEM. *p b 0.05; **p b 0.01; ***p b 0.001.
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gregates in the cell lines studied here.3.5. Intracellular L12P protein aggregates inmouse hepatocytes— evidence
from an in vivo approach
In order to further explore the selective existence of L12P TTR in-
tracellular aggregates in hepatocytes in the liver, we used systemic
gene delivery with adeno-associated virus (AAV) vectors encoding
WT, V30M or L12P TTR under a liver-speciﬁc promoter. The viral
stocks were administrated to TTR null mice through tail vein injec-
tions. The animals were euthanized 3 months later and characterized
for infection efﬁciency, TTR liver expression and TTR serum levels.
AAV vector genomes were quantiﬁed in the liver, stomach and in
the peripheral nervous system by qPCR. We found that liver was the
only organ where signiﬁcant amounts of AAV vector genome copies
per mouse genome were found, with identical levels of viral genome
copies across groups of mice injected with AAV vectors encoding WT,
V30M or L12P TTR (Supplemental data, Fig. S3).
The human identity of TTR proteins in sera was evaluated by mass
spectrometry following immunoprecipitation and conﬁrmed (data
not shown). TTR levels were then measured by ELISA; whereas mice
expressing humanWT or V30M TTR had comparable levels of the pro-
tein in their sera (~5-fold lower than in transgenic animal models),
TTR-L12P levels were approximately 10-fold lower than the other
isoforms (Fig. 6A), despite equal levels of liver viral genome copies
per mouse genome, as above described. We next carried out western
blot analysis of sera (Fig. 6B); as shown in Fig. 6B, in addition to the
regular TTR monomer, a higher molecular weight band of approxi-
mately 2 kDa higher was detected in the sera of L12P TTR expressing
mice, suggesting the existence of N-glycosylated L12P-TTR in sera. As
shown above, this additional band was present in western blots of
conditioned media from SaHep cells expressing L12P or D18G TTR
variants (Fig. 2A and C), which N-glycosidase F treatment conﬁrmed
to represent a product of N-glycosylation.We then investigated by immunoﬂuorescence, TTR localization in
the liver of these animals. Animals expressing TTR L12P displayed in-
tracellular TTR aggregates in liver hepatocytes (Fig. 6C), which were
not present in the livers of WT and V30M-TTR animals that had a dif-
fused staining owing to TTR secretion. Further confocal immunoﬂuo-
rescence analysis of L12P aggregates with the lysosomal marker
Lamp-2 indicated co-localization in lysosomes (Fig. 6C), as earlier
found in L12P expressing SaHep cells.
All together, data from “in vitro” hepatocyte-derived cells and the
newly developed L12Pmice conﬁrmed theunique properties of thismu-
tant, as prone to N-glycosylation, poorly secreted by liver, and forming
intracellular aggregates degraded by the lysosomal proteolytical system.4. Discussion
In the ﬁeld of amyloid diseases opinions differ considerably on
how and where amyloid ﬁbrils are formed. In TTR amyloidoses, it is
commonly accepted that TTR variants aggregate in the extracellular
environment [34], since the protein is secreted as a correctly folded
product after undergoing quality control where misfolded proteins
are targeted for ERAD degradation [8,18]. The present report concen-
trated on a special TTR variant previously reported to deposit in the
liver of a L12P patient [3], in complete contrast with the most com-
mon V30M TTR variant, which led us to hypothesize particular, ab-
normal cell trafﬁcking properties for the L12P variant.
The systems used to tackle the in vitro and in vivo studies of this
work were very advantageous because of the following: (i) were car-
ried out on established cell lines derived from TTR naturally produc-
ing cells without endogenous TTR expression; as such the in vivo
conditions are mimicked in a much better way as compared to the
use of transient transfections [35]; (ii) allowed in vivo labeling with
a small tag, and lentiviral vectors generated high stable expression
of WT and TTR variants in the different cell types used; and (iii) sys-
temic administration of the AAV vectors resulted in highly selective
and stable liver expression of WT and V30M or L12P variants
Fig. 5. Effect of rapamycin in TTR secretion. A. Intracellular distribution of TTR-TC (green) compared to LC3 A/B (red). Note that the vast majority of TTR punctated aggregates do not
co-localize with autophagosomes, with a few exceptions in the SaHep cell line, pointed by arrowheads. Scale bars, 5 μm. Nuclei are stained with Hoechst 33342 (blue). Plots rep-
resent hTTR levels in conditioned media with and without rapamycin treatment (B) measured by ELISA and in cell lysates (C) relative to a-tubulin. Error bars represent SEM.
*p b 0.05; **p b 0.01; ***p b 0.001.
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adverse immunological reactions were noticed (data not shown).
Both approaches revealed a wealth of new data; ﬁrst, cell culture
experiments on the L12P variant, showed clear and distinct secretionproperties between hepatocytes and choroid plexus cells. While
WT-TTR and the V30M variant are secreted by both hepatocytes and
choroid plexus cells, the D18G and the L12P leptomeningeal associat-
ed TTR mutants signiﬁcantly differed between the two cell types with
Fig. 6. In vivo TTR expression in mice. (A) hTTR concentration in sera of WT, V30M and L12P mice as measured by ELISA. Error bars represent SEM. *** p b 0.001; (B) TTR western
blot of sera from L12P and WT mice, showing a high molecular weight N-glycosylated L12P TTR band above the TTR monomer, absent from WT serum. Arrows indicate the
N-glycosylated band (a) and TTR monomer (b). C. TTR distribution in mice hepatocytes. TTR (green) expression is widespread in mice hepatocytes after transduction with AAV
vectors. The presence of intracellular TTR aggregates is evident in hepacocytes in the TTR L12P mouse with noticeable green punctated staining. These punctuates are not seen
in models for TTR WT and V30M. L12P aggregates localize in lysosomes (Lamp-2 staining, red), pointed by white arrowhead. Scale bars, 10 μm. Nuclei are stained with DAPI
(blue). Plots represent extent of co-localization by measuring the distance between the highest intensity of the different channels on selected points of the ﬁgure.
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cytes as assessed by in vivo labeling and biochemical methods, but
not in TR-CSFB cells. Previous studies on the D18G variant using an
immortalized rat choroidal epithelial cell line (Z310 cells) showed re-
tention of this variant [8]. However, the immortalization procedures
used across cell lines can be very different, which may explain secre-
tion of D18G in CP-derived lines used in the present work; TR-CSFB
cells are choroid plexus cells derived from transgenic rats harboring
a temperature-sensitive SV40 large T-antigen gene (ts SV40), and
are thus a conditionally immortalized cell line. In contrast, the Z310
cell line was immortalized by transfection with the viral plasmid
psV3neo. One of the main advantages of conditionally immortalized
cell lines derived from such transgenic animals is that transgene in-
sertion is unlikely to have disrupted essential genes as these homozy-
gous animals are viable and have been maintained for many years
[20]. In contrast immortalization via transfection of primary cells
may lead to unpredictable insertional mutagenesis with the potential
to affect pathways important to the biology of TTR; at any rate, there
is always the possibility that cell lines in culture display different se-
cretion rates and/or protein quality control properties compared to
hepatocytes in their native environment in the liver. Only in vivo ap-
proaches can deﬁnitely resolve and corroborate the cell culture data.
The hepatic AAV-mediated somatic transgenesis approach we used
here to assess the in vivo properties of L12P supports our ﬁndings
in hepatocytes in culture, and represents a new approach to rapidly
evaluate properties of TTR variants.
Secondly, we report for the ﬁrst time N-glycosylation of L12P by
hepatocyte-like cells and secretion of a glycosylated product. Different
types of post-translational modiﬁcations in TTR have been reported
[36–39]. N-glycosylation of TTR at asparagine 118 (Asn-118) [38] has
been described; however the function of this post-translationalmodiﬁcation is yet to be clariﬁed. More recently, Sato and colleagues
[25] demonstrated that highly destabilized misfolded TTR variants
such as D18G, but not the WT or V30M, can be N-glycosylated on posi-
tion 98 (Asn-98) and targeted to an EDEM3-mediated N-glycan depen-
dent ERAD tomaintain cellular homeostasis. TTR possesses a sequon for
N-glycosylation at position 98 (Asn-Asp-Ser) [40], but normal protein
folding usually hides this sequence into the interior of the molecule,
however protein unfolding might expose this sequon to the surface
[41]. N-glycosylation can improve the thermodynamic and kinetic sta-
bility of a protein [42]; therefore the low ratio of glycosylated form to
non-glycosylated suggests that most protein exists as a moderately un-
folded form and only a small fraction is severely unfolded and exposes
the N-glycosylation sequon [25].
Wehypothesize that themechanismunderlying L12PN-glycosylation
is similar to what has been described for blood coagulation factor VII
(FVII), which is post-transcriptionally glycosylated after accumulation
in the ER followed by folding into a secretion-competent conformation
[43], since in our studies increased levels of ER chaperones, like BiP,
Herp or HRD1 were not noticeable in hepatocyte derived cells (data
not shown), therefore N-glycosylation of L12P TTR is not targeting it
for Herp-associated ERAD degradation. Furthermore, very recently the
existence of N-glycosylated V30M TTR in the plasma of FAP patients
was described, but the authors failed to identify N-glycosylated protein
in tissue extracts of transgenic V30Mmice [40]; taken together we hy-
pothesize that severely unfolded L12P TTR is retained inside the cell for
lysosomal degradation whereas aminute amount isN-glycosylated and
secreted as a glycosylated product.
The assays involving tunicamycin, an N-glycosylation inhibitor,
showed a decrease in secretion of L12P TTR in hepatocytes (Fig. 2D)
but it did not affect choroid plexus cells secretion (data not shown);
we thus hypothesize that choroid plexus may not possess the
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to their secretion, suggesting that N-glycosylation of this particular
amyloidogenic TTR variant is important for protein secretion by hepato-
cytes but not by choroid plexus. Moreover, the different glycosylation
patterns may also be the explanation on why the choroid plexus de-
rived cells secrete TTR L12P at levels comparable to WT TTR, whereas
in the other cell lines secretion of this variant is considerably reduced,
possibly to overcome extensive extracellular accumulation that might
cause toxicity. Description of secretion of N-glycosylated TTR was un-
equivocally demonstrated in the serum of L12Pmice.Whether this rep-
resents an escape to N-glycosylation-dependent ERAD is the subject of
future investigation, and in this regard, the L12P mutant constitutes a
model system, both by in vitro and in vivo approaches.
Thirdly, the study we present here shows by in vivo labeling the
targeting to the lysosome of intracellular produced TTR aggregates. Pre-
vious studies with the D18G mutant hypothesize accumulation and
degradation of intracellular TTR by ERAD mechanisms, both indepen-
dent and dependent on N-glycosylation. Most cells possess forms of
protein degradation alternate to ERAD and the UPS. One of alternative
processes is macroautophagy, which takes place in lysosomes. This pro-
cess is involved in diseaseswhere intracellular protein accumulation oc-
curs, as it is the case inMachado–Joseph disease wheremutant ataxin-3
is cleared in the lysosomes [44], or Parkinson's disease, where
α-synuclein is translocated for degradation in lysosomes [45]. There-
fore, it is not surprising that intracellular L12P TTR aggregates (and
D18G) can follow this pathway for degradation. Disposal of TTR aggre-
gates by autophagy might also operate but only when the lysosomal
degradation system is impaired [32]. Absence of TTR aggregates in the
lysosomal compartment of choroid plexus derived cells again stresses
the possibility of still unknown secretion and quality control properties
assigned of this cell type. Lysosomal accumulation of TTR aggregates in
the liver of L12P mice not only corroborated the cell culture data, but
also raises the potential to use somatic transgenesis in tests of pharma-
cological compounds to improve lysosomal clearance in instances of
liver TTR intracellular aggregates. Such class of compounds is the subject
of intense study for other protein aggregation related disorders, as for
instance in a rat model of Machado–Joseph disease where
over-expression of beclin-1 improved the lysosomal clearance of
ataxin-3 [44].
Finally, a new animal model was generated using recombinant AAV
vectors instead of the more usual transgenic mouse. Viral-vector-
mediated gene transfer has the advantage of being targeted to a partic-
ular organ, gene expression can be induced at any time-point during de-
velopment or in the fully mature animal and high levels of gene
expression can be achieved [46].
Our animalmodel expresses the protein only in liver, due to the liver
speciﬁc promoter present in our constructs. Because the viral load in
liver was similar among TTR variants and the WT protein, the 10
times lower serum levels found for L12P animals compared to WT or
V30M animals is related to the unique intracellular retention/degrada-
tion of the L12P protein in liver; these aggregates were not present in
neither WT nor V30M animals.
Previous studies have compared TTR levels both in serumandCSF, as
well as across variants. These have shown that V30M carriers have re-
duced levels of TTR in serum than non-carriers [47]; the same occurring
in the case of TTR variants associated with leptomeningeal amyloidosis
[48], and in the particular case of L12P carriers the reduction in TTR
serum levels goes from the normal concentration range 0.2–0.4 g/L to
0.11 g/L [49], a reduction of about 50%. However, in CSF no differences
were observed in the TTR concentration across mutations [48].
Overall our in vivo approach replicates the data we described for the
cell line model. But more importantly, it replicates the clinical features
found in patients, in particular the severe protein deposition in liver
[3] and opens a newdoor to the establishment of somatic transgenic an-
imal models for different TTR variants. There are still many questions
lacking answers, including why some particular TTR variants appearto cause CNS amyloidosis if all are secreted and not retained by the cho-
roid plexus? CNS sensitivity or protein afﬁnity to tissuesmight certainly
play an important role? At any rate, through the in vitro system new
therapeutic approaches to leptomeningeal amyloidosis encompassing
trapping TTR inside the cell and enhancing lysosomal degradation sys-
tem to avoid the presence of aggregates in CNS warrant further
investigation.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2013.04.001.Acknowledgements
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